A Phase 2 interventional study of Afrezza in Type 1 Diabetes Mellitus, sponsored by Mannkind Corporation. Completed at 13 sites in United States. Open to participants aged 4 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-04-06.
Sponsored by Mannkind Corporation · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1 — 1 open to participants now, 1 under way, none of them phase 3. Insulin, Regular, Human · Diabetes Mellitus, Type 1.
Among the 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1, this one is the 23rd largest by enrollment, is one of 2 that started in 2017, is one of 8 in phase 2, and was the 29th registered.
3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →1 of the 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1 is open now, in 1 country. Recruiting first, the newest first:
Mannkind Corporation · Sites in United States
Ages 6–17
By country, each count listing its studies:
Insulin, Regular, Human: first FDA approval 1982 (HUMULIN R PEN), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →
Of the 412 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 258 (63%) stop at 75 or younger; 185 take children under 18; 64 take healthy volunteers.
This study: 4 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 9 · Phase 3 17 · Phase 4 4
First in 1989; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 40 across 2,820 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 74 across the 35 interventional studies. Of the 34 that completed or were terminated, 10 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 35 have an industry lead sponsor. The 10 most frequent:
Mannkind Corporation is the lead sponsor of 57 studies on the registry; 3 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 3 (38%) have results posted.
21 studies in Diabetes Mellitus, Type 1 by Mannkind Corporation: 1 open now, 1 under way, none of them phase 3. Of 19 finished, 10 (53%) have results posted.
Among the 21 studies in Diabetes Mellitus, Type 1 by Mannkind Corporation, this one is the 11th largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2017, is one of 5 in phase 2, and was the 16th registered.
Mannkind Corporation’s Diabetes Mellitus, Type 1 studies by the year they started, since 2005.
1 of the studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07224321Mannkind CorporationINHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes | 2027-03 |
Add it to your calendar (.ics) → With an account.
Among the 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Mannkind Corporation’s 21 in Diabetes Mellitus, Type 1:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary Objective:
-To assess the safety and tolerability of Afrezza in children ages 4 to 17 years with type 1 diabetes mellitus (T1DM).
Secondary Objectives:
The patients are expected to participate in the study for approximately 6 to 8 weeks from Screening to final follow-up visit.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Individualized dose of Afrezza (Technosphere Insulin) for each patient at each meal (breakfast, lunch, and dinner) for 30 days. During the trial, all patients will receive multiple injections of basal long acting insulin, in general at bedtime every day.
Biological: Afrezza
Pharmaceutical form: powder Route of administration: inhalation
Also known as: Technosphere Insulin
Insulin Maximum Observed Concentration (Cmax)
Insulin Cmax after a dose of Afrezza
Time frame: 250 minutes post-dose
Insulin Time to Reach Cmax (Tmax)
Insulin Tmax after a dose of Afrezza
Time frame: 250 minutes post-dose
Insulin Area Under Concentration Time Curve (AUC)
Insulin AUC after a dose of Afrezza
Time frame: 250 minutes post-dose
Assessment of Fumaryl Diketopiperazine (FDKP) Elimination Half-life (t1/2)
FDKP (inert carrier excipient) calculated half life t1/2
Time frame: Using PK data collected over 250 minutes post-dose of Afrezza
| Milestone | Afrezza Cohort 1 (Ages 13-17) | Afrezza Cohort 2 (Ages 8-12) |
|---|---|---|
| Started | 15 | 15 |
| Completed | 13 | 11 |
| Not completed | 2 | 4 |
Insulin Cmax after a dose of Afrezza
| μU/mL | Afrezza Cohort 1 (Ages 13-17) | Afrezza Cohort 2 (Ages 8-12) |
|---|---|---|
| 4 unit cartridge | 28.5 ± 5.77 | 102 ± 31.4 |
| 8 unit cartridge | 101 ± 42.1 | 133 ± 91.0 |
| 12 unit cartridge | 201 ± 118 | 251 ± NA |
| 16 unit cartridge | 105 ± NA | — |
Insulin Tmax after a dose of Afrezza
| minutes | Afrezza Cohort 1 (Ages 13-17) | Afrezza Cohort 2 (Ages 8-12) |
|---|---|---|
| 4 unit cartridge | 12.5 ± 3.54 | 9.5 ± 4.04 |
| 8 unit cartridge | 13.5 ± 5.47 | 14.1 ± 5.44 |
| 12 unit cartridge | 15.3 ± 3.27 | 10.0 ± NA |
| 16 unit cartridge | 20.0 ± NA | — |
Insulin AUC after a dose of Afrezza
| min*μU/mL | Afrezza Cohort 1 (Ages 13-17) | Afrezza Cohort 2 (Ages 8-12) |
|---|---|---|
| 4 unit cartridge | 1468 ± 1272 | 2931 ± 1011 |
| 8 unit cartridge | 4488 ± 2644 | 4975 ± 2921 |
| 12 unit cartridge | 6400 ± 3009 | 5971 ± NA |
| 16 unit cartridge | 5778 ± NA | — |
FDKP (inert carrier excipient) calculated half life t1/2
| minutes | Afrezza Cohort 1 (Ages 13-17) | Afrezza Cohort 2 (Ages 8-12) |
|---|---|---|
| 4 unit cartridge | 103 ± 23.0 | 86.8 ± 6.35 |
| 8 unit cartridge | 123 ± 31.3 | 86.5 ± 15.8 |
| 12 unit cartridge | 109 ± 25.9 | 95.5 ± NA |
| 16 unit cartridge | 144 ± NA | — |
Collected over 4 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Afrezza Cohort 1 (Ages 13-17) | 0/15 (0%) | 1/15 (6.7%) | 12/15 (80%) |
| Afrezza Cohort 2 (Ages 8-12) | 0/15 (0%) | 1/15 (6.7%) | 11/15 (73.3%) |
| Event | Afrezza Cohort 1 (Ages 13-17) | Afrezza Cohort 2 (Ages 8-12) |
|---|---|---|
| Gastroenteritis viralInfections and infestations | 0/15 | 1/15 |
| Diabetic ketoacidosisMetabolism and nutrition disorders | 1/15 | 0/15 |
| Event | Afrezza Cohort 1 (Ages 13-17) | Afrezza Cohort 2 (Ages 8-12) |
|---|---|---|
| HypoglycemiaMetabolism and nutrition disorders | 10/15 | 10/15 |
| CoughRespiratory, thoracic and mediastinal disorders | 7/15 | 5/15 |
| Upper respiratory tract infectionInfections and infestations | 1/15 | 3/15 |
| DysmenorrheaReproductive system and breast disorders | 2/15 | 0/15 |
| Throat irritationRespiratory, thoracic and mediastinal disorders | 1/15 | 0/15 |
| Tonsillar hypertrophyRespiratory, thoracic and mediastinal disorders | 0/15 | 1/15 |
| GastroenteritisInfections and infestations | 1/15 | 0/15 |
| Urinary tract infectionInfections and infestations | 1/15 | 0/15 |
| ConstipationGastrointestinal disorders | 1/15 | 0/15 |
| DiarrhoeaGastrointestinal disorders | 1/15 | 0/15 |
| Age, Continuous(years) | Afrezza Cohort 1 (Ages 13-17) | Afrezza Cohort 2 (Ages 8-12) | Total |
|---|---|---|---|
| Mean | 15.0 ± 1.73 | 10.4 ± 1.55 | 12.7 ± 2.84 |
| Sex: Female, Male(Participants) | Afrezza Cohort 1 (Ages 13-17) | Afrezza Cohort 2 (Ages 8-12) | Total |
|---|---|---|---|
| Female | 8 | 10 | 18 |
| Male | 7 | 5 | 12 |
| Ethnicity (NIH/OMB)(Participants) | Afrezza Cohort 1 (Ages 13-17) | Afrezza Cohort 2 (Ages 8-12) | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 2 | 2 |
| Not Hispanic or Latino | 15 | 13 | 28 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Afrezza Cohort 1 (Ages 13-17) | Afrezza Cohort 2 (Ages 8-12) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 1 | 3 |
| White | 12 | 13 | 25 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 1 | 2 |
| Region of Enrollment(participants) | Afrezza Cohort 1 (Ages 13-17) | Afrezza Cohort 2 (Ages 8-12) | Total |
|---|---|---|---|
| United States | 15 | 15 | 30 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2017 to primary completion in Mar 2020, 29 months.
Results were first posted in Apr 2021, 1 year after primary completion.
Of 50 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 33. This study's 29 months is above that.
Counting every sponsor, half of 133 studies reached it within 36 months; a quarter within 17 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin, Regular, Human